Anaplastic large cell lymphoma: changes in the World Health Organization classification and perspectives for targeted therapy

Haematologica. 2009 Jul;94(7):897-900. doi: 10.3324/haematol.2009.008250.

Abstract

The accompanying perspective by Drs. Falini and Martelli provides a clear description of the current WHO classification with a focus on the distinction between ALK-positive anaplastic large cell lymphoma ALCL and ALK-negative disease. Additionally, they provide a rationale for potential new targets for therapy including flavopiridol. See related paper on page 944.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Anaplastic Lymphoma Kinase
  • Biomarkers, Tumor / metabolism
  • Cell Proliferation
  • Humans
  • Immunohistochemistry / methods
  • Ki-1 Antigen / biosynthesis
  • Lymph Nodes / pathology
  • Lymphatic Metastasis
  • Lymphoma, Large-Cell, Anaplastic / classification*
  • Lymphoma, Large-Cell, Anaplastic / diagnosis*
  • Medical Oncology / methods*
  • Mutation
  • Prognosis
  • Protein-Tyrosine Kinases / biosynthesis
  • Receptor Protein-Tyrosine Kinases
  • Translocation, Genetic
  • World Health Organization

Substances

  • Biomarkers, Tumor
  • Ki-1 Antigen
  • Anaplastic Lymphoma Kinase
  • Protein-Tyrosine Kinases
  • Receptor Protein-Tyrosine Kinases